Evaluation of the Impact of the Use of the Digital Solution NewSpringForMe on Transplanted Patients' Quality of Life and Support (Bone Marrow or Peripheral Stem Cells Allotransplantation)

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

Bone marrow transplantation is both a great treatment for patients with hematological diseases. It is also one of the only hopes of staying alive by starting from scratch. It is a trying life experience, at all its stages. To support these patients and increase their success in healing and returning to a normal life, quality of life is an ally of choice for the success of care. NewSpringForMe is an innovative tool designed for the benefit of transplant patients, through the deployment of unprecedented interdisciplinary support benefiting from the best digital technologies. This digital solution is aimed at all patients, adults and pediatrics, before, during and after bone marrow transplantation, in a long-term approach. NewSpringForMe results from the multidisciplinary collaboration of medical and paramedical experts in the field of hematology and transplantation, as well as in the field of psychology. With NewSpringForMe, each transplant patient has a personalized and scalable space accessible via a web platform, constantly offering, according to their needs and at their own pace, a range of recommendations, tools and exercises in psychology, nutrition / dietetics and physical activity, the three pillars of overall well-being. Perfectly integrated into the care pathway and the transplant protocol, from the announcement of the treatment to the long-term follow-up, several years after the intervention, NewSpringForMe complements the medical treatments provided by the medical profession: the communication of the assessments from the platform as well as patient data for caregivers allows adaptation of therapies and optimization of medical care. Thanks to the consideration of individual parameters and their evolution, and thanks to specific algorithms, each tool is adapted to the course of care and to the life of each patient, as well as to their personal health situation throughout their transplant journey. In order to demonstrate the benefits of using NewSpringForMe, the project plans to evaluate the platform and its impact on the quality of life in patients with hematological diseases. This evaluation will be done by the patients themselves and by the nursing staff. The evaluation will be carried out using a monocentric approach on a pilot cohort. The objective is to demonstrate that integrative health ensuring simultaneous care of body and mind increases the chances of success of the transplant while limiting post-transplant complications.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• at least 18 years old

• with a first indication for allograft bone marrow or Peripheric Stem Cells

• monitored by the adult hematology transplant department St-Louis Hospital

• having signed the consent

• affiliated to a social security scheme

• able to understand the objectives of the study and to use a digital tool

Locations
Other Locations
France
Service Hématologie Greffe Trèfle 3, Hôpital Saint-Louis, AP-HP
RECRUITING
Paris
Contact Information
Primary
Emilie Robert, PhD
emilie.robert@htcproject.org
33 4 91 11 88 53
Backup
Régis Peffault de Latour, PU-PH
regis.peffaultdelatour@aphp.fr
Time Frame
Start Date: 2022-09-27
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 170
Treatments
NewSpringForMe cohort
Patients with hematological diseases intended to be allotransplanted (bone marrow or Hematopoietic Stem Cells)
Related Therapeutic Areas
Sponsors
Collaborators: Clinicprosport, Association Aïda, Novartis Pharmaceuticals, University Hospital, Clermont-Ferrand, Groupe Apicil, LAPSCO, Université Clermont-Auvergne, Gilead Sciences, Saint-Louis Hospital, Paris, France, Pierre Fabre Medicament, Fondation AFNIC, Pfizer, Association Laurette Fugain, ELLYE, Nutricia Nutrition Clinique, Fondation du LEEM
Leads: Fonds de Dotation HTC Project

This content was sourced from clinicaltrials.gov